Many people with hemophilia A can lead ordinary, active lives. Learning more about this genetic condition can support effective long-term management strategies. Hemophilia A is a genetic condition ...

Sangamo Therapeutics’ stock has plummeted by 50% in premarket trading after Pfizer ended the companies’ partnership to co-develop a gene therapy for haemophilia A. Sangamo announced it will ...

For centuries, hemophilia was a dangerous genetic disorder with no treatment. Children with hemophilia often didn't make it to adulthood, since a bump or fall could cause massive internal bleeding.

A recent study led by MedUni Vienna provides new insights into the mechanisms of coagulation in persons with haemophilia A, the most common form of haemophilia. The research team was able to show that ...

Financial writer discusses MGX's gene editing technology, cash runway, and lack of clinical data for potential future ...

Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement.

After having a bad experience getting three vaccines at once, columnist Jennifer Lynne says that next time, she'll space them apart.

Haemophilia a rare hereditary blood disorder that prevents proper blood clotting affects millions globally and as there is no ...

Growing advancements in haemophilia treatment underscore a significant shift toward targeted and long-lasting therapeutic ...